Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we forecast the number of drug-treatment opportunities in specific lines of therapy for countries throughout the world.
DRG Epidemiology's renal cell carcinoma forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with renal cell carcinoma per year?
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with renal cell carcinoma per year?
- How will improvements in survival change the number of people living with a diagnosis of renal cell carcinoma?
- Of all people diagnosed with renal cell carcinoma, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of renal cell carcinoma over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following renal cell carcinoma patient populations:
- Diagnosed incident cases by stage distribution.
- Diagnosed non-resectable metastatic first-line DTP by drug treatment.
- Diagnosed non-resectable metastatic first-line DTP by recurrence.
- Diagnosed prevalent cases by drug-treatment potential.
- Drug-treatable prevalent cases by resection potential.
… and more (details available on request).
Note: Coverage may vary by country and region.
- Renal Cell Carcinoma - Epidemiology - Americas
Author(s): Ema Rodrigues, DSc, MPH; Nishant Kumar, MPH
Ema is an epidemiologist with expertise in forecasting incident and prevalent populations within oncology, as well as some cardiovascular indications such as venous thromboembolism. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables.
She completed her master’s and doctoral degree (MPH, D.Sc.) in Environmental Health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes including central nervous system cancer, cognitive function, and birth outcomes.
Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects.
His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.